Search clinical trials for: Budesonid or budesonide/fomoterol administered by MDI

Total 246 results

Cipla Ltd.

Completed

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

Asthma

United States
Orion Corporation, Orion Pharma

Completed

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Laval University
AstraZeneca

Completed

Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects (D5890L00013)

Asthma

Canada
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients (SUMIRE)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Russian Federation, Vietnam, Philippines, Ukraine, Japan, Taiwan, India
AstraZeneca

Completed

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans (Titan)

Asthma

United States
AstraZeneca

Completed

Gemini Symbicort pMDI

Mild or Moderate Asthma
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
AstraZeneca

Completed

Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM

Asthma
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
AstraZeneca

Completed

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg (CHASE 3)

Asthma

United States, Mexico, Slovakia, Panama
Zambon SpA

Completed

A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers

Asthma

United Kingdom
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Chronic Obstructive Pulmonary Disease

China
Franciscus Gasthuis
Teva Pharmaceuticals USA

Recruiting

Expertise Asthma COPD Program With Digital Support (EXACT@home)

Asthma

Netherlands
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (REFLI)

Asthma

Germany
AstraZeneca

Completed

Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy (RELEASE)

Asthma

United Kingdom
Stanford University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

ARrest RESpiraTory Failure From PNEUMONIA (ARREST)

Pneumonia | COVID-19 Pneumonia | Hypoxemia | Acute Respiratory Failure

United States
Imperial College London
AstraZeneca

Completed

Effect of Symbicort on GR Localisation in Asthma

Asthma

United Kingdom
Medical University of Lodz

Completed

Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma

Asthma

Poland
Zambon SpA

Completed

Clinical Study to Evaluate Z7200 Pharmacokinetics Profile

Asthma

United Kingdom
GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
AstraZeneca

Completed

A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

Asthma

United States
AstraZeneca

Completed

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

Asthma

United States
AstraZeneca

Completed

A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

Pulmonary Disease, Chronic Obstructive

United Kingdom
AstraZeneca

Completed

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

Asthma | Airway Inflammation

United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Bronchiectasis | COPD

China
Government Medical College, Bhavnagar

Completed

Controller Medications in the Management of Bronchial Asthma

Moderate to Severe Persistent Bronchial Asthma

India
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

Asthma

Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Orion Corporation, Orion Pharma

Completed

Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics (KINECO)

Asthma

United Kingdom
Centre Hospitalier Intercommunal Creteil
AstraZeneca

Terminated

Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (ASTHMAFAST)

Asthma in Children

France
AstraZeneca

Completed

A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan

Chronic Obstructive Pulmonary Disease

Japan
AstraZeneca

Completed

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Asthma

Croatia
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
AstraZeneca

Recruiting

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (VATHOS)

Asthma

United States, Canada, Italy, Japan, Vietnam, Spain, Germany, Malaysia
AstraZeneca

Completed

Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) (SECURE 1)

Chronic Obstructive Pulmonary Disease (COPD)

Korea, Republic of, China, Hong Kong, Thailand, Indonesia
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
AstraZeneca

Completed

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (REALITY)

Perception of Physicians & Patients of AMD
AstraZeneca

Completed

SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma

Asthma

Sweden
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Chronic Obstructive Pulmonary Disease

France
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
AstraZeneca

Completed

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

Asthma

Malaysia
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Germany, Hungary, Romania, Denmark, Greece, Mexico, Iceland
AstraZeneca

Completed

Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD (CODEX)

Chronic Obstructive Pulmonary Disease

Germany, Switzerland
AstraZeneca

Completed

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

Stable Asthma

3

Subscribe